Answers are grounded in this paper and cite their sources.
The integration of artificial intelligence (AI) into healthcare is accelerating, with dermatology standing out as a key field where AI's potential is evident. In 2025, Ireland seeks to implement Sláintecare and transform its health and social care system by establishing a universal, single-tier, person-centred service. Sláintecare declares its goal to be ‘improving health and social care services in Ireland, to optimise patient outcomes and be responsive to their needs’. With such ambitious goals, one obvious aid could be the embracing of AI in medicine and, in particular, the dermatology sector. AI, particularly deep learning algorithms, has already demonstrated impressive diagnostic accuracy in dermatology, particularly for identifying skin cancers like melanoma. Studies indicate that AI can match, and in some cases surpass, experienced clinicians in diagnostic performance [1, 2]. Yet, despite its potential, AI is not yet a regular tool in Irish dermatology departments. Ireland's first rapid access teledermatology service Dermview was founded in 2018, in the hope of reducing waiting times and increase access. However, many clinics face challenges in adapting to this model. Telemedicine has been met with scepticism by dermatologists in the assessment of conditions such as the diagnosis of pigmented lesions [3]. Dermatology in Ireland faces a substantial patient backlog. At the time of writing, there are over 50,000 people currently waiting for an appointment [4, 5]. The number of dermatologists per 100,000 people is one of the lowest in Europe, further exacerbating this issue [4]. AI could be instrumental in alleviating some of these pressures, such as by triaging referrals, assisting with mole mapping or identifying high-priority lesions. This would not only reduce waiting times but also improve care for those in underserved rural areas [6]. Despite AI's demonstrated successes, its widespread adoption faces several hurdles. One of the major challenges is clinician scepticism. A global survey revealed that 22% of dermatologists are unsure about AI's reliability and its role in patient management [7]. This scepticism is compounded by the emotional difficulty of accepting that a machine, with only a few years of existence, might outperform a clinician with decades of experience. However, AI's achievements in other domains, such as radiological imaging, clearly highlight its capability to learn and adapt. Another challenge is patient trust, which is likely to be earned, not given. Studies show that while patients tend to trust dermatologists over AI, their attitudes towards AI improve as they see its benefits. Trust can be fostered through transparent communication and patient engagement. Over time, as AI demonstrates its efficacy in clinical settings, both clinicians and patients may become more accepting of its role in diagnosis and management [8]. AI in dermatology is already showing promise globally. For instance, convolutional neural networks (CNNs) are highly effective in detecting skin cancer, and teledermatology platforms like DermView have enhanced remote care. Additionally, predictive analytics powered by AI could optimise treatment pathways and reduce unnecessary wait times [1]. Ireland's growing health tech sector, abundance of multinational tech corporations such as Google and Meta, combined with its highly educated workforce and strong academic institutions provide an opportunity to lead the way in AI adoption. However, the country must address several issues: ensuring that training datasets reflect its increasingly diverse population, navigating regulatory challenges and overcoming clinician resistance. Establishing national databases for AI model development during the reform of its healthcare service, launching pilot programs and incorporating AI into dermatology training programs could further streamline the process. The integration of AI into dermatology in Ireland could also contribute to a wider momentum shift across Europe. As health systems across the EU struggle with rising demand, workforce shortages and increasing expectations for equitable access, successful implementation in one country can serve as a catalyst for regional adoption. One paper notes regional differences within Europe, with European respondents expressing both optimism and reservations about AI integration, especially regarding diagnostic reliability and job security [9]. However, should Ireland be successful in adopting AI within dermatology as well as improve its ability to use electronic medical records (EMR), we could potentially pave the way for effective, efficient data sharing with benefits for both patients, doctors and researchers. Thus, a coordinated, Europe-wide approach could therefore accelerate both innovation and trust in AI-driven dermatology. AI offers transformative potential for dermatology in Ireland and potentially many countries within Europe, by potentially improving diagnostic accuracy and reducing patient waiting times. With strategic investment, enhanced education and collaboration with international tech companies, Ireland has the opportunity to lead the charge in AI-driven dermatology and could serve as the spark that ignites broader transformation across Europe. The author has drafted the manuscript and critically reviewed its content autonomously. The author has nothing to report. The author declares no conflicts of interest. Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Geoffrey Hanley (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: